TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03928106

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacists' recommendation
Description: For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacists' recommendation
Description: For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.
Study: NCT00694265

Intervention type: PROCEDURE
Intervention: Decompression
Description: Surgical decompression of the median nerve

Intervention type: PROCEDURE
Intervention: Conservative treatment
Description: Conservative treatment typically consisted of splinting and corticosteroid injections
Study: NCT02908841

Intervention type: DEVICE
Group type: OTHER
Intervention: Surgicel Snow

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Study: NCT00696644

Intervention type: DRUG
Intervention: Teriparatide
Description: 20 mcg daily subcutaneous for 18 months.
Study: NCT01654406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser and pulsed dye laser
Description: Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed dye laser
Description: Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
Study: NCT03560479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha1H, 7.4 mg/mL
Description: Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha1H, 37 mg/mL
Description: Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha1H, 74 mg/mL
Description: Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
Study: NCT02827331

Intervention type: OTHER
Intervention: Exposition to hypnotics or anxiolytics benzodiazepines
Description: Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Benzodiazepine derivatives (N05BA)~* Benzodiazepine derivatives (N05CD)~* Benzodiazepine related drugs (N05CF)

Intervention type: OTHER
Intervention: Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics
Description: Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Antipsychotics (N05A)~* Antiepileptics with the exception of clonazepam (N03)~* Drugs used for alcohol dependance (N07BB)~* Drugs used for opioids dependance (N07BC)

Intervention type: OTHER
Intervention: Medical consultation without prescription
Description: Medical consultation without prescription of any drugs of interest
Study: NCT03601130

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HydroxyColl Bone Graft Substitute
Description: The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)
Description: The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.

Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)
Description: The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
Study: NCT00275574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture
Study: NCT02667067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplify Disc
Description: Simplify Disc at one level in the cervical spine.

Intervention type: DEVICE
Group type: OTHER
Intervention: Anterior Cervical Discectomy & Fusion
Description: This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®\|C Disc trial.
Study: NCT01015937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric extract
Description: turmeric 500 mg TID for 45 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric extract
Description: turmeric 500 mg TID for 45 days
Study: NCT02046109

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Replace
Study: NCT01839773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Study: NCT02416258

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LP0113 aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LP0113 aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LP0113 aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LP0113 aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LP0113 aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosol spray vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosol spray vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosol spray vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosol spray vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosol spray vehicle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 aerosol foam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam
Study: NCT01015937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
Description: maximum dosage as patient tolerated for 45 days
Study: NCT04368351

Intervention type: DIETARY_SUPPLEMENT
Intervention: SivoMixx (200 billion)
Description: Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)

Intervention type: DRUG
Intervention: Azithromycin
Description: dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)

Intervention type: DRUG
Intervention: Azithromycin
Description: dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)

Intervention type: DRUG
Intervention: hydroxychloroquine
Description: dose: 200 mg, 1 cp x 2 / day

Intervention type: DRUG
Intervention: hydroxychloroquine
Description: dose: 200 mg, 1 cp x 2 / day
Study: NCT02416258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betamethasone dipropionate aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone dipropionate aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone dipropionate aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone dipropionate aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone dipropionate aerosol spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcipotriol aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol aerosol spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol aerosol spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daivobet® gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® gel
Study: NCT01683955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Topical tranexamic acid (2g/100mL 0.9% saline)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL 0.9% sterile saline
Study: NCT00293644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclectin®
Description: Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
Study: NCT04039607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive ipilimumab as IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Participants will receive sorafenib as oral tablets.
Study: NCT00293644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclectin®
Description: Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
Study: NCT01822405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxifylline with tocopherol
Description: Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy
Description: pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.~Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment.
Study: NCT01133301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg/d Naltrexone will be administrated during three weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: 50 mg/d Naltrexone will be administrated during three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: During 3 weeks of the study, Placebo will be administrated (daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During 3 weeks of the study, Placebo will be administrated (daily)
Study: NCT01124136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation + Medication Management (Standard of Care)
Description: In addition to medication management, adding investigational implanted neurostimulator to heart
Study: NCT02252406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets daily for 24 weeks.
Study: NCT01124136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (Control)
Description: Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care (Control)
Description: Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
Study: NCT01669733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The control group subjects will receive standard anesthesia, nursing and surgical care.
Study: NCT02394847

Intervention type: DRUG
Group type: OTHER
Intervention: propofol
Study: NCT04057014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic given at different dosages and durations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic given at different dosages and durations.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
Study: NCT06168110

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment method widely used for pain control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment method widely used for pain control
Study: NCT04106661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Physical activity requiring slow, controlled whole body movement and weight shifting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Physical activity requiring slow, controlled whole body movement and weight shifting.
Study: NCT03829787

Intervention type: DEVICE
Intervention: Eye tracking
Description: Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology

Intervention type: DEVICE
Intervention: Eye tracking
Description: Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology

Intervention type: DEVICE
Intervention: Eye tracking
Description: Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
Study: NCT03116191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-1404
Description: 4 weeks of repeated administration of SK-1404 to the patients of nocturia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks of repeated administration of Placebo to the patients of nocturia
Study: NCT04489576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)
Description: Hair will be treated with 2 different types of keratin in groups 1 \& 2. All steps of keratin application will be done in group 3 without keratin application as a control group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)
Description: Hair will be treated with 2 different types of keratin in groups 1 \& 2. All steps of keratin application will be done in group 3 without keratin application as a control group.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)
Description: Hair will be treated with 2 different types of keratin in groups 1 \& 2. All steps of keratin application will be done in group 3 without keratin application as a control group.
Study: NCT00748891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recentin (Cediranib)
Description: 30mg once daily, oral dose
Study: NCT04329585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flumazenil
Description: EEG is observed in both groups to compare the difference between two groups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo is the normal saline, which is given in the controlled group.
Study: NCT02518399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
Study: NCT04039607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenvatinib
Description: Participants will receive lenvatinib as oral capsules.
Study: NCT01341301

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Undergo TBI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Undergo DLI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic HSCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study: NCT03752268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Cancer Pain Management
Description: Patients will learn and practice an enduring framework of cognitive-behavioral strategies, to enhance adherence behavior, reduce intentional and unintentional deviations from the prescribed regimen.
Study: NCT03622021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111 or Placebo
Description: All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111 or Placebo
Description: All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111 or Placebo
Description: All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111 or Placebo
Description: All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111 or Placebo
Description: All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111 or Placebo
Description: All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
Study: NCT00706329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deflux
Description: Patients undergo surgery using Deflux to correct umbilical hernia